Tocilizumab for hospitalized patients with COVID-19.
作者信息
Afra Kevin, Chen Luke Y C, Sweet David
机构信息
Division of Infectious Diseases (Afra) and Division of Hematology (Chen), Department of Medicine; Department of Emergency Medicine (Sweet); and Centre for Health Education Scholarship (Chen), University of British Columbia; Division of Critical Care (Sweet), Department of Medicine, Vancouver General Hospital, Vancouver, BC; Division of Infectious Diseases (Afra), Department of Medicine, Fraser Health Authority, Surrey, BC
Division of Infectious Diseases (Afra) and Division of Hematology (Chen), Department of Medicine; Department of Emergency Medicine (Sweet); and Centre for Health Education Scholarship (Chen), University of British Columbia; Division of Critical Care (Sweet), Department of Medicine, Vancouver General Hospital, Vancouver, BC; Division of Infectious Diseases (Afra), Department of Medicine, Fraser Health Authority, Surrey, BC.
出版信息
CMAJ. 2021 Apr 12;193(15):E521. doi: 10.1503/cmaj.210066. Epub 2021 Mar 9.
Abstract
摘要
相似文献
1
Tocilizumab for hospitalized patients with COVID-19.托珠单抗用于住院的新冠肺炎患者。
CMAJ. 2021 Apr 12;193(15):E521. doi: 10.1503/cmaj.210066. Epub 2021 Mar 9.
2
COVID-19, steroids and other immunomodulators: The jigsaw is not complete.新型冠状病毒肺炎、类固醇及其他免疫调节剂：拼图尚未完成。
Anaesth Crit Care Pain Med. 2020 Dec;39(6):699-701. doi: 10.1016/j.accpm.2020.10.011. Epub 2020 Oct 25.
3
Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.托珠单抗治疗中重度 COVID-19 患者：一项回顾性队列研究。
J Clin Pharm Ther. 2021 Apr;46(2):440-446. doi: 10.1111/jcpt.13303. Epub 2020 Oct 24.
4
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
5
The shortcomings of tocilizumab in COVID-19.托珠单抗在治疗新型冠状病毒肺炎中的不足之处。
Infez Med. 2020 Dec 1;28(4):465-468.
6
Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.音频访谈：一种新型的严重急性呼吸综合征冠状病毒2疫苗以及对治疗方法的新审视
N Engl J Med. 2021 Mar 4;384(9):e46. doi: 10.1056/NEJMe2103680.
7
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
8
Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.托珠单抗治疗与 COVID-19 患者临床结局的相关性：系统评价和荟萃分析。
Aging (Albany NY). 2022 Jan 17;14(2):557-571. doi: 10.18632/aging.203834.
9
SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy.新型冠状病毒2型（SARS-CoV-2）疫苗接种在多发性硬化症中的应用：关于CD20清除疗法期间时间点的更清晰情况。
EBioMedicine. 2021 Nov;73:103635. doi: 10.1016/j.ebiom.2021.103635. Epub 2021 Oct 14.
10
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析，首次更新。
Clin Microbiol Infect. 2021 Aug;27(8):1076-1082. doi: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27.
引用本文的文献
1
Tumour necrosis factor-alpha inhibitors decrease mortality in COVID-19: a systematic review and meta-analysis.肿瘤坏死因子-α抑制剂可降低COVID-19的死亡率：一项系统评价和荟萃分析。
Crit Care. 2025 Jun 6;29(1):232. doi: 10.1186/s13054-025-05420-9.
2
ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients.ABO血型与新冠病毒病严重程度：与危重症患者内皮细胞和脂肪细胞激活的关联
PLoS One. 2025 Apr 2;20(4):e0320251. doi: 10.1371/journal.pone.0320251. eCollection 2025.
3
The role of C-reactive protein and ferritin in the diagnosis of HLH, adult-onset still's disease, and COVID-19 cytokine storm.C反应蛋白和铁蛋白在噬血细胞性淋巴组织细胞增生症、成人斯蒂尔病及新型冠状病毒肺炎细胞因子风暴诊断中的作用
Sci Rep. 2024 Dec 28;14(1):31306. doi: 10.1038/s41598-024-82760-6.
4
Anti-viral effect of usenamine a using SARS-CoV-2 pseudo-typed viruses.乌司他丁胺A对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）假型病毒的抗病毒作用。
Heliyon. 2023 Oct 28;9(11):e21742. doi: 10.1016/j.heliyon.2023.e21742. eCollection 2023 Nov.
5
COVID-19 therapies for inpatients: a review and quality assessment of clinical guidelines.COVID-19住院患者治疗方法：临床指南综述与质量评估
ERJ Open Res. 2022 Nov 21;8(4). doi: 10.1183/23120541.00236-2022. eCollection 2022 Oct.
6
Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study.与基于体重给药相比，在新冠肺炎危重症患者中降低托珠单抗固定剂量至400mg静脉注射：一项前后队列研究。
Lancet Reg Health Am. 2022 Jul;11:100228. doi: 10.1016/j.lana.2022.100228. Epub 2022 Mar 23.
本文引用的文献
1
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
2
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.直面争议：白细胞介素-6 与 COVID-19 细胞因子风暴综合征。
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.03006-2020. Print 2020 Oct.
Zotero 插件